42
Participants
Start Date
September 4, 2019
Primary Completion Date
February 13, 2024
Study Completion Date
February 13, 2024
Trikafta
Participants will take Trikafta which is a combination tablet comprised of 100 milligrams (mg) of elexacaftor, 50 mg of tezacaftor and 75 mg of ivacaftor (2 tablets taken in the morning), and 150 mg of ivacaftor taken in the evening.
Emory Children's Center, Atlanta
University of Alabama Cystic Fibrosis Research Center, Birmingham
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Cystic Fibrosis Foundation
OTHER
The University of Texas Health Science Center, Houston
OTHER
Emory University
OTHER